Physician profile
James E Clarkson
NPI 1285711978
$2,170.99
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $513 · 2021: $70.91 · 2022: $100 · 2023: $176 · 2024: $33.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $209.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $235.16 | 2019-2022 | |
| Incyte Corporation | $187.19 | 2019-2020 | |
| Celgene Corporation | $161.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $151.66 | 2019-2023 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $146.09 | 2020-2021 | |
| Amgen INC. | $138.25 | 2019-2020 | |
| Genentech USA, INC. | $111.96 | 2019 | |
| Verastem, INC. | $104.34 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $101.88 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $98.35 | 2020-2023 | Pyrukynd |
| Janssen Biotech, INC. | $97.86 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $87.61 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $79.91 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $49.93 | 2019-2021 | |
| Genzyme Corporation | $43.72 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $43.66 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $33.78 | 2024 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $31.90 | 2019 | |
| Abbvie INC. | $30.08 | 2019-2020 | |
| Array Biopharma INC | $29.03 | 2020 | |
| Taiho Oncology, INC. | $21.35 | 2019 | |
| Seagen INC. | $18.81 | 2020 | |
| Astellas Pharma US INC | $18.75 | 2019 | |
| Biocompatibles, INC. | $17.79 | 2019 | |
| Exelixis INC. | $16.51 | 2019 | |
| Acceleron Pharma, INC. | $16.24 | 2020 | |
| Kyowa Kirin, INC. | $14.89 | 2019 | |
| Tesaro, INC. | $14.59 | 2019 | |
| Coherus Oncology, INC. | $14.52 | 2020 | |
| Emd Serono, INC. | $14.45 | 2019 | |
| Puma Biotechnology, INC. | $14.39 | 2019 | |
| Foundation Medicine, INC. | $12.39 | 2020 | |
| Lilly USA, LLC | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Clarkson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.